crizanlizumab
Novartis’ sickle cell drug reduces vaso-occlusive crises by 35% at Phase 2
October 10, 2018Research and Development Novartis, crizanlizumab, pharma, sickle cell disease
Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
